JPH047725B2 - - Google Patents

Info

Publication number
JPH047725B2
JPH047725B2 JP59141081A JP14108184A JPH047725B2 JP H047725 B2 JPH047725 B2 JP H047725B2 JP 59141081 A JP59141081 A JP 59141081A JP 14108184 A JP14108184 A JP 14108184A JP H047725 B2 JPH047725 B2 JP H047725B2
Authority
JP
Japan
Prior art keywords
aspirin
intravenous
cancer
administered
parvum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59141081A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6122018A (ja
Inventor
Tsunetaka Nakajima
Masahiro Watanabe
Masayuki Nishida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GC Biopharma Corp
Original Assignee
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Korea filed Critical Green Cross Corp Korea
Priority to JP59141081A priority Critical patent/JPS6122018A/ja
Publication of JPS6122018A publication Critical patent/JPS6122018A/ja
Publication of JPH047725B2 publication Critical patent/JPH047725B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP59141081A 1984-07-06 1984-07-06 癌免疫療法増強剤 Granted JPS6122018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59141081A JPS6122018A (ja) 1984-07-06 1984-07-06 癌免疫療法増強剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59141081A JPS6122018A (ja) 1984-07-06 1984-07-06 癌免疫療法増強剤

Publications (2)

Publication Number Publication Date
JPS6122018A JPS6122018A (ja) 1986-01-30
JPH047725B2 true JPH047725B2 (https=) 1992-02-12

Family

ID=15283765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59141081A Granted JPS6122018A (ja) 1984-07-06 1984-07-06 癌免疫療法増強剤

Country Status (1)

Country Link
JP (1) JPS6122018A (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171783A (ja) * 1997-08-15 1999-06-29 Vetoquinol Sa 所定の動物に関して細胞性免疫と体重増加を生じる濃度でのバクテリアの経口投与
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Also Published As

Publication number Publication date
JPS6122018A (ja) 1986-01-30

Similar Documents

Publication Publication Date Title
EP0726772B1 (en) A method for sensitization of cancer cells for killer cell mediated lysis
JP3140021B2 (ja) Ｔｎｆ阻害剤含有医薬組成物
Chirigos et al. Augmentation of chemotherapeutically induced remission of a murine leukemia by a chemical immunoadjuvant
IT8922725A1 (it) Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
EP0116693A1 (en) An immunopotentiator having spermidine or its pharmacologically acceptable salt as active ingredient
JPH10139670A (ja) インターロイキン１２誘導物質及び医薬組成物
JPH047725B2 (https=)
Youn et al. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid
Larionov Some biological and clinical results from the investigations of the chloroethylamines as anti-tumour drugs
JPH02111727A (ja) 免疫反応が減少したときの免疫系のためのインターロイキン―２の使用
Fisher et al. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. V. Comparison of the effects of tilorone hydrochloride, levamisole, methanol-soluble fraction of Mycobacterium butyricum, BCG, and a nonviable aqueous ether extract of Brucella abortus preparation in treatment of mice with tumors
Friedman Induction of immune response to protein antigens by subcutaneous co-injection with water-miscible vitamin A derivatives
US6288074B1 (en) Method of treating lymphoproliferative syndrome
JPS6365653B2 (https=)
JP3459268B2 (ja) 抗癌剤
JP2004508290A (ja) 免疫調節における粒状ベクターの使用
JPH045005B2 (https=)
Ferdinandi et al. Virulizin®-a review of its antineoplastic activity
Alley et al. Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
Morales et al. Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers
NL8401226A (nl) Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
Katz The allogeneic effect on the immune system and its potential application to tumour immunity
OKURA et al. Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice
JP2001081047A (ja) 経口摂取用製剤